Stay updated with breaking news from Atripla Tablets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The company has received approval for Efavirenz (600mg), Emtricitabine (200mg), Tenofovir Disproxil Fumurate (300mg), (EET) tablets from the United States Food & Drug Administration (USFDA).
The company's product is bioequivalent and therapeutically equivalent to Atripla Tablets of Gilead Sciences LLC, it added. As per per IQVIA, Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumurate tablet (EET) has a market opportunity of USD 7.5 million in the US.
Strides Pharma Science on Wednesday said its subsidiary has received approval from the US health regulator to market a generic version of Gilead Sciences' Atripla tablets which are indicated to help control HIV infection. Singapore-based Strides Pharma Global, a stepdown wholly-owned subsidiary of